ZOTAROLIMUS
ZOTAROLIMUS Basic information
- Product Name:
- ZOTAROLIMUS
- Synonyms:
-
- ZOTAROLIMUS
- (42S)-42-Deoxy-42-(1H-tetrazol-1-yl)rapamycin
- A 179578
- ABT 578
- ABT-578;A-179578;ABT578;A179578;ABT 578;A 179578
- CS-1162
- Rapamycin, 42-deoxy-42-(1H-tetrazol-1-yl)-, (42S)-
- Unii-H4gxr80ize
- CAS:
- 221877-54-9
- MF:
- C52H79N5O12
- MW:
- 966.21
- Product Categories:
-
- Inhibitors
- Chiral Reagents
- Intermediates & Fine Chemicals
- Pharmaceuticals
- Heterocycles
- Mol File:
- 221877-54-9.mol
ZOTAROLIMUS Chemical Properties
- Melting point:
- 100-105°C
- Boiling point:
- 1016.2±75.0 °C(Predicted)
- Density
- 1.25
- storage temp.
- Hygroscopic, -20°C Freezer, Under Inert Atmosphere
- solubility
- DMSO, Methanol (Slightly)
- form
- Solid
- pka
- 10.40±0.70(Predicted)
- color
- White to Pale Yellow
ZOTAROLIMUS Usage And Synthesis
Description
Zotarolimus is a macrocyclic lactone immunosuppressant and a derivative of rapamycin . It binds to FKBP prolyl isomerase 1A (FKBP12; IC50 = 2.57 nM) and inhibits proliferation of human peripheral blood mononuclear cells (PBMCs), rat splenocytes, and human coronary artery smooth muscle cells (IC50s = 7, 1,337, and 0.8 nM, respectively). Zotarolimus has immunosuppressive activity in a one-way mixed lymphocyte reaction using human or rat lymphocytes (IC50s = 1.2 and 1,465 nM, respectively). It also reduces symptom severity in a rat model of experimental autoimmune encephalomyelitis (EAE; ED50 = 1.17 mg/kg per day) and delays cardiac allograft rejection in rats (ED50 = 3.71 mg/kg per day). Zotarolimus inhibits neointimal formation and reduces stenosis in pig coronary arteries when applied at 10 μg/mm to stainless steel balloon expandable stents with phosphorylcholine in a model of restenosis. Formulations containing zotarolimus have been used in drug-eluting stents in the prevention of restenosis following stent placement.
Chemical Properties
Pale Yellow Solid
Uses
Zotarolimus is a semi-synthetic macrocyclic lactone prepared from rapamycin by preparation of the 42-triflate ester, followed by displacement with tetrazole and purification of the two isomeric products. This structural change affords a less bioavailable product, a preferred profile for some applications. Like all tacrolimus analogues, zotarolimus binds to a receptor protein (FKBP12). The complex then binds to preventing it from interacting with target proteins. Zotarolimus is extensively cited in the literature with over 200 citations.
Uses
A tetrazole-containing Rapamycin analog as immunomodulator and useful in the treatment of restenosis and immune and autoimmune diseases.
Definition
ChEBI: Zotarolimus is a macrolide and a lactam.
ZOTAROLIMUSSupplier
- Tel
- 010-82848833 400-666-7788
- jkinfo@jkchemical.com
- Tel
- +86-21-20908456
- sales@BioChemBest.com
- Tel
- 1-(800)-881-8210
- inquiries@lgmpharma.com
- Tel
- 021-50135380
- shchemsky@sina.com
- Tel
- 0411-62910999 13889544652
- meilunui@163.com
ZOTAROLIMUS(221877-54-9)Related Product Information
- AZD 3759
- (2R)-1-{4-[(1aR,6r,10bS)-1,1-Difluoro-1,1a,6,10b-tetrahydrodibenzo[a,e]cyclopropa[c]cyclohepten-6-yl]piperazin-1-yl}-3-(quinolin-5-yloxy)propan-2-ol
- Zonisamide
- Z-NLE-OH
- ZM 336372
- ZM 39923 HYDROCHLORIDE
- Z-NVA-OH
- Z-N-Methyl-D-valine
- Z-ORN(BOC)-OH
- ZPCK
- Tepotinib
- Saracatinib
- Dasatinib
- Trametinib
- Epothilone B
- Ruxolitinib
- ZOSUQUIDAR TRIHYSROCHLORIDE
- Rapamycin